trial data News & Analysis

Ideaya Biosciences (IDYA) Price Target Raised After Trial Data Release

Oppenheimer has increased the price target for Ideaya Biosciences (IDYA) based on new trial data. The specific new price target has not been disclosed in the article. This adjustment reflects the firm's confidence in IDYA's clinical development, potentially impacting investor sentiment and trading volumes. The update is significant for stakeholders and may influence Ideaya's market positioning moving forward.